AR033987A1 - Compuestos calcioliticos y su uso en la fabricacion de medicamentos - Google Patents
Compuestos calcioliticos y su uso en la fabricacion de medicamentosInfo
- Publication number
- AR033987A1 AR033987A1 ARP010103456A ARP010103456A AR033987A1 AR 033987 A1 AR033987 A1 AR 033987A1 AR P010103456 A ARP010103456 A AR P010103456A AR P010103456 A ARP010103456 A AR P010103456A AR 033987 A1 AR033987 A1 AR 033987A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- compounds
- ring
- alkyl
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- AQTFKGDWFRRIHR-UHFFFAOYSA-L 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;cobalt(2+);hydron Chemical compound [Co+2].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 AQTFKGDWFRRIHR-UHFFFAOYSA-L 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 230000004079 mineral homeostasis Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Compuestos calciolíticos o sus sales farmacéuticamente aceptables útiles para el tratamiento de una serie de enfermedades asociadas con la homeostasis ósea o mineral anormal. Tales compuestos están representados por la fórmula (1), donde: A representa C o N con uno o dos N en el anillo I; D representa C o N con uno o dos N en el anillo II que está unido en la posición 4 o 5 al anillo I como se indica; X se selecciona del grupo constituido por CN, NO2, Cl, F y H; Y se selecciona cuando A es C del grupo constituido por Cl, F, Br, I y H; Q se selecciona cuando D es C del grupo constituido por H, R1, SO2R1', R1C(O)OR1', tetrazol, CH2OH, COH, SO2NR1'R1'', C(O)NR1'R1'', y NR1SO2R1', donde R1 se selecciona independientemente del grupo constituido por un enlace, hidrógeno, alquilo C1-4, y alquilo opcionalmente sustituido; R1', y R1'' se seleccionan independientemente del grupo constituido por hidrógeno, alquilo C1-4 y alquilo opcionalmente sustituido, o R1' y R1'' forman juntos un anillo heterocíclico de 3 a 7 miembros opcionalmente sustituido. Ar es fenilo o naftilo, sustituido o no, heterarilo o heteroarilo condensado. También se da a conocer el uso de dichos compuestos en la fabricación de medicamentos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21984200P | 2000-07-21 | 2000-07-21 | |
| US22063600P | 2000-07-25 | 2000-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033987A1 true AR033987A1 (es) | 2004-01-21 |
Family
ID=26914307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103456A AR033987A1 (es) | 2000-07-21 | 2001-07-20 | Compuestos calcioliticos y su uso en la fabricacion de medicamentos |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1368318B1 (es) |
| JP (1) | JP2004509077A (es) |
| KR (1) | KR20030017642A (es) |
| CN (1) | CN1582275A (es) |
| AR (1) | AR033987A1 (es) |
| AT (1) | ATE380177T1 (es) |
| AU (2) | AU2001276923B2 (es) |
| BR (1) | BR0112600A (es) |
| CA (1) | CA2416537A1 (es) |
| CZ (1) | CZ2003142A3 (es) |
| DE (1) | DE60131781T2 (es) |
| ES (1) | ES2296774T3 (es) |
| HU (1) | HUP0300758A2 (es) |
| IL (1) | IL154058A0 (es) |
| MX (1) | MXPA03000556A (es) |
| MY (1) | MY133881A (es) |
| NO (1) | NO325333B1 (es) |
| PL (1) | PL365703A1 (es) |
| WO (1) | WO2002007673A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE411275T1 (de) | 2000-08-11 | 2008-10-15 | Japan Tobacco Inc | Calciumrezeptor-antagonisten |
| MY143244A (en) | 2002-11-26 | 2011-04-15 | Smithkline Beecham Corp | Calcilytic compounds |
| JP3751312B2 (ja) | 2003-04-23 | 2006-03-01 | 日本たばこ産業株式会社 | ＣａＳＲアンタゴニスト |
| JPWO2004106280A1 (ja) | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | ＣａＳＲアンタゴニスト |
| US20070270446A1 (en) * | 2004-10-06 | 2007-11-22 | Smithkline Beecham Corporation | Reversed Pyrimidinone Compounds as Calcilytics |
| EP2128136A4 (en) * | 2006-12-12 | 2012-01-04 | Nippon Zoki Pharmaceutical Co | DERIVATIVE OF 2-PHENYLNICOTINIC ACID |
| CN102056897B (zh) | 2008-06-05 | 2014-05-07 | 旭化成制药株式会社 | 磺酰胺化合物及其用途 |
| WO2015089842A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Novel tricyclic calcium sensing receptor antagonists for the treatment of osteoporosis |
| UY36548A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
| WO2024160842A1 (en) | 2023-01-30 | 2024-08-08 | Medizinische Universität Wien | Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158956A (en) * | 1990-05-04 | 1992-10-27 | Eli Lilly And Company | Method of inhibiting gastric acid secretion with benzodioxanes |
| US5258379A (en) * | 1990-05-04 | 1993-11-02 | Eli Lilly And Company | Method of inhibiting gastric acid secretion with n-arylpiperazines |
| ATE298739T1 (de) * | 1996-04-09 | 2005-07-15 | Nps Pharma Inc | Calcylitische verbindungen |
| AR014975A1 (es) * | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
-
2001
- 2001-07-16 PL PL01365703A patent/PL365703A1/xx not_active Application Discontinuation
- 2001-07-16 MX MXPA03000556A patent/MXPA03000556A/es active IP Right Grant
- 2001-07-16 EP EP01954696A patent/EP1368318B1/en not_active Expired - Lifetime
- 2001-07-16 BR BR0112600-8A patent/BR0112600A/pt not_active Application Discontinuation
- 2001-07-16 ES ES01954696T patent/ES2296774T3/es not_active Expired - Lifetime
- 2001-07-16 CN CNA018131166A patent/CN1582275A/zh active Pending
- 2001-07-16 AT AT01954696T patent/ATE380177T1/de not_active IP Right Cessation
- 2001-07-16 IL IL15405801A patent/IL154058A0/xx unknown
- 2001-07-16 WO PCT/US2001/022267 patent/WO2002007673A2/en not_active Ceased
- 2001-07-16 AU AU2001276923A patent/AU2001276923B2/en not_active Expired - Fee Related
- 2001-07-16 AU AU7692301A patent/AU7692301A/xx active Pending
- 2001-07-16 DE DE60131781T patent/DE60131781T2/de not_active Expired - Fee Related
- 2001-07-16 HU HU0300758A patent/HUP0300758A2/hu unknown
- 2001-07-16 JP JP2002513411A patent/JP2004509077A/ja not_active Withdrawn
- 2001-07-16 CA CA002416537A patent/CA2416537A1/en not_active Abandoned
- 2001-07-16 CZ CZ2003142A patent/CZ2003142A3/cs unknown
- 2001-07-16 KR KR10-2003-7000846A patent/KR20030017642A/ko not_active Ceased
- 2001-07-19 MY MYPI20013427 patent/MY133881A/en unknown
- 2001-07-20 AR ARP010103456A patent/AR033987A1/es not_active Application Discontinuation
-
2003
- 2003-01-20 NO NO20030303A patent/NO325333B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2416537A1 (en) | 2002-01-31 |
| NO20030303L (no) | 2003-03-20 |
| WO2002007673A3 (en) | 2003-10-16 |
| CN1582275A (zh) | 2005-02-16 |
| NO325333B1 (no) | 2008-03-31 |
| HUP0300758A2 (hu) | 2003-08-28 |
| KR20030017642A (ko) | 2003-03-03 |
| DE60131781T2 (de) | 2008-12-24 |
| WO2002007673A2 (en) | 2002-01-31 |
| EP1368318B1 (en) | 2007-12-05 |
| IL154058A0 (en) | 2003-07-31 |
| NO20030303D0 (no) | 2003-01-20 |
| CZ2003142A3 (cs) | 2003-06-18 |
| AU2001276923B2 (en) | 2005-02-03 |
| EP1368318A4 (en) | 2006-08-23 |
| ATE380177T1 (de) | 2007-12-15 |
| MXPA03000556A (es) | 2003-06-06 |
| BR0112600A (pt) | 2003-06-24 |
| EP1368318A2 (en) | 2003-12-10 |
| JP2004509077A (ja) | 2004-03-25 |
| DE60131781D1 (de) | 2008-01-17 |
| AU7692301A (en) | 2002-02-05 |
| PL365703A1 (en) | 2005-01-10 |
| MY133881A (en) | 2007-11-30 |
| ES2296774T3 (es) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
| UY27368A1 (es) | Nuevos compuestos | |
| UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| DE60132975D1 (de) | Neue substanzen und verbindungen als protease-inhibitoren | |
| BRPI0112986B8 (pt) | compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| BR0315665A (pt) | Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento | |
| TR200200648T2 (tr) | Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri. | |
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| AR041969A1 (es) | Medicamento para el tratamiento de la enfermedad pulmonar obstructiva cronica | |
| SE9904508D0 (sv) | New compounds | |
| CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
| EE05287B1 (et) | Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| BR0312513A (pt) | Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| GT200100196A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7. | |
| AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
| ATE302774T1 (de) | Arzneimittel enthaltend betamimetika und ein neues anticholinergikum | |
| AR033987A1 (es) | Compuestos calcioliticos y su uso en la fabricacion de medicamentos | |
| SE0102055D0 (sv) | New Compounds | |
| MX9307946A (es) | Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. | |
| UY26720A1 (es) | Derivados del pirrol | |
| SE0002476D0 (sv) | New compounds | |
| ES2083708T3 (es) | Nuevas piperazinilalcoil-3 dihidro-2,3,4h-benzoxazina-1,3 onas-4 sustituidas, su preparacion y su aplicacion en terapeutica. | |
| CO5540322A2 (es) | Nuevos derivados heterociclicos que comprenden un anillo de tetrahidroisoquinolina y uso farmaceutico de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |